OpenAlex Citation Counts

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cannabinoid Receptor Type 2 Ligands: An Analysis of Granted Patents Since 2010
Benjamin Brennecke, Thais Gazzi, Kenneth Atz, et al.
Pharmaceutical Patent Analyst (2021) Vol. 10, Iss. 3, pp. 111-163
Closed Access | Times Cited: 24

Showing 24 citing articles:

Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Mauro Maccarrone, Vincenzo Di Marzo, Jürg Gertsch, et al.
Pharmacological Reviews (2023) Vol. 75, Iss. 5, pp. 885-958
Open Access | Times Cited: 90

Structural basis of selective cannabinoid CB2 receptor activation
Xiaoting Li, Hao Chang, Jara Bouma, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 46

A GPCR-based yeast biosensor for biomedical, biotechnological, and point-of-use cannabinoid determination
Karel Miettinen, Nattawat Leelahakorn, Aldo Almeida, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 43

CIRCE: Web-Based Platform for the Prediction of Cannabinoid Receptor Ligands Using Explainable Machine Learning
Nicola Gambacorta, Fulvio Ciriaco, Nicola Amoroso, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 18, pp. 5916-5926
Closed Access | Times Cited: 22

Potential of CBD Acting on Cannabinoid Receptors CB1 and CB2 in Ischemic Stroke
Iu Raïch, Jaume Lillo, Rafael Rivas‐Santisteban, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6708-6708
Open Access | Times Cited: 6

Allosterism in the adenosine A_2A and cannabinoid CB₂ heteromer
Claudia Llinás del Torrent, Iu Raïch, Ángel González, et al.
British Journal of Pharmacology (2024)
Open Access | Times Cited: 6

Recent Advances on Type-2 Cannabinoid (CB₂) Receptor Agonists and their Therapeutic Potential
Valeria Gasperi, Tatiana Guzzo, Alessandra Topai, et al.
Current Medicinal Chemistry (2022) Vol. 30, Iss. 12, pp. 1420-1457
Closed Access | Times Cited: 18

Exploring the 1,3-benzoxazine chemotype for cannabinoid receptor 2 as a promising anti-cancer therapeutic
Nicola Gambacorta, Valeria Gasperi, Tatiana Guzzo, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115647-115647
Closed Access | Times Cited: 10

Patent review of cannabinoid receptor type 2 (CB ₂ R) modulators (2016-present)
Miroslav Kosar, Leonard Mach, Erick M. Carreira, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 8, pp. 665-700
Closed Access | Times Cited: 3

Cannabinoid receptor 2 (CB2) modulators: A patent review (2016–2024)
Rayees Ahmad Naikoo, Ritu Painuli, Zaheen Akhter, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107775-107775
Closed Access | Times Cited: 3

Exploring the Antibacterial Potential of Semisynthetic Phytocannabinoid: Tetrahydrocannabidiol (THCBD) as a Potential Antibacterial Agent against Sensitive and Resistant Strains of Staphylococcus aureus
Pankaj Singh Cham, Deepika, Rahul Bhat, et al.
ACS Infectious Diseases (2023) Vol. 10, Iss. 1, pp. 64-78
Closed Access | Times Cited: 7

Dual allosteric and orthosteric pharmacology of synthetic analog cannabidiol-dimethylheptyl, but not cannabidiol, on the cannabinoid CB2 receptor
Jara Bouma, Jeremy D. Broekhuis, Cas van der Horst, et al.
Biochemical Pharmacology (2023) Vol. 218, pp. 115924-115924
Open Access | Times Cited: 5

CB2R agonists in the clinics: A treasure chest for treating inflammatory diseases
Uwe Grether, Marc Nazaré
Open Access Government (2023) Vol. 39, Iss. 1, pp. 218-219
Open Access | Times Cited: 2

Challenges bringing CB₂R medicine to bedside
Pál Pacher, Uwe Grether
Open Access Government (2023) Vol. 37, Iss. 1, pp. 22-23
Open Access | Times Cited: 2

Synthetic Pathways to Non-Psychotropic Phytocannabinoids as Promising Molecules to Develop Novel Antibiotics: A Review
Silvana Alfei, Gian Carlo Schito, Anna Maria Schito
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1889-1889
Open Access | Times Cited: 1

Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships: Insights from Roche’s Endocannabinoid System Projects
Johannes D. Aebi, Kenneth Atz, Simon M. Ametamey, et al.
CHIMIA International Journal for Chemistry (2024) Vol. 78, Iss. 7-8, pp. 499-512
Open Access

Chemical Probes for Investigating the Endocannabinoid System
Annaleah Hanske, Marc Nazaré, Uwe Grether
Current topics in behavioral neurosciences (2024)
Closed Access

Is CB₂R a hidden treasure trove for treating inflammatory diseases?
Mauro Maccarrone, Uwe Grether
Open Access Government (2022) Vol. 36, Iss. 1, pp. 28-29
Open Access | Times Cited: 1

Development of Yin-Yang ligand for cannabinoid receptors
Y. L. Qiu, Yitian Zhao, Tao Hu, et al.
Bioorganic Chemistry (2023) Vol. 133, pp. 106377-106377
Closed Access

CB₂R ligands to treat inflammatory diabetes
Uwe Grether, Marc Nazaré
Open Access Government (2023) Vol. 40, Iss. 1, pp. 224-225
Open Access

A GPCR-based yeast biosensor for biomedical, biotechnological, and point-of-use cannabinoid determination
Karel Miettinen, Nattawat Leelahakorn, Aldo Almeida, et al.
Research Square (Research Square) (2022)
Open Access

Displacement Binding Assay Using Human Cannabinoid CB2 Receptor-Transfected Cells
Maria Grazia Cascio, Pietro Marini, Roger G. Pertwee
Methods in molecular biology (2022), pp. 111-118
Closed Access

Cyclic AMP Assay Using Human Cannabinoid CB2 Receptor-Transfected Cells
Pietro Marini, Maria Grazia Cascio, Roger G. Pertwee
Methods in molecular biology (2022), pp. 171-179
Closed Access

Patents Targeting Cannabinoid Receptor Type 2 Ligands: An Interview with Uwe Grether
Uwe Grether
Pharmaceutical Patent Analyst (2021) Vol. 10, Iss. 4, pp. 175-177
Closed Access

Page 1

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Analytics" category .
cookielawinfo-checkbox-functional	1 year	The cookie is set by the GDPR Cookie Consent plugin to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Necessary" category .
cookielawinfo-checkbox-others	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Others".
cookielawinfo-checkbox-performance	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSID	session	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.

Requested Article:

Showing 24 citing articles:

Your Privacy